Trial Profile
Phase 1 Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Miransertib (Primary)
- Indications Proteus syndrome
- Focus Adverse reactions; Pharmacodynamics
- 29 Jun 2022 Status changed from active, no longer recruiting to completed.
- 25 Feb 2019 According to an ArQule media release, data were published in the American Journal of Human Genetics.
- 02 Oct 2018 Status changed from recruiting to active, no longer recruiting.